DiscoveryBioMed Awarded $300,000 National Institutes of Health (NIH) Grant for Cystic Fibrosis Drug Research and Development

Published: Oct 28, 2009

BIRMINGHAM, Ala.--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

Back to news